-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $25

Benzinga·09/03/2026 10:20:43
语音播报
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $50 to $25.